

Proven Obesity Trial Experience

Remington-Davis (RDI) runs an established obesity research platform. The site consistently meets or exceeds enrollment targets, recruits fast early on, and keeps participants engaged through dietitian-supported retention. Experienced investigators lead the work, and the site can capably scale patient access as programs grow.



Key stats:

- 12 obesity studies in the portfolio
- 60 participants enrolled in the first weight-loss study
- 100% of enrollment targets met or exceeded to date
- ~99% reported retention across obesity studies
- Four dietitians supporting participants
- Thousands of prescreened obesity candidates in the active pipeline

Why Remington-Davis?

- RDI meets sponsor enrollment needs in a timely fashion, with a pool of patients ready to enroll after that initial period.
- Four sponsors have awarded or planned more than one obesity program with the site, and the portfolio includes 10 confirmed Phase III programs.
- A dedicated obesity-interest pipeline keeps candidates engaged and segmented by protocol fit, so they're ready when a new study opens.
- Average reported Black participant representation across obesity studies runs 34.4%, with one trial reaching 36%.

Experienced Investigator Leadership

Roy C. St. John, MD and Edward M. Cordasco, DO serve as investigators on the current profile of obesity studies. Both are board-certified in Pulmonary and Critical Care Medicine and each bring more than three decades of clinical expertise and healthcare leadership. Their combined obesity portfolio covers uncomplicated obesity, T2D, hypertension, and cardiovascular disease.

Obesity Retention Strategy

- **Dietitian-led support:** Four dietitians prepare participants for expected side effects and provide individualized mitigation, nutrition, and ongoing management.
- **Proactive education:** Expectation-setting starts before treatment and continues through early visits, so participants know what to expect and how to respond.
- **High-touch follow-up:** Frequent check-ins, fast escalation of symptoms, and responsive clinical communication catch concerns before they affect participation.
- **Visit enablement:** Flexible scheduling, reminders, transportation support when needed, and personalized follow-up cut barriers to continued participation.

Demonstrated Study Experience

Without disclosing sponsor- or protocol-specific details, the summary below shows the site's experience across weight loss and cardiometabolic obesity populations.

Study population	Participant profile	Phase / status	Enrollment result	Retention
Weight loss	Adults with obesity without diabetes	Phase II Completed	Met or exceeded	99%
Obesity with hypertension	Adults with obesity and hypertension	Phase III Enrollment closed	Met or exceeded	99%
Weight loss	Adults with obesity	Phase III Enrolling	Ongoing	Ongoing
Weight loss	Overweight adults	Phase III Enrollment closed	Met or exceeded	99%
Obesity with T2D	Adults with obesity and type 2 diabetes	Phase III Enrolling	Ongoing	Ongoing
Weight loss with T2D	Overweight adults with type 2 diabetes	Phase III Enrollment closed	Met or exceeded	100%
Obesity with CV disease	Adults with obesity and CV disease	Phase III Upcoming	N/A	N/A
Weight loss	Adults with obesity with or without type 2	Phase III Upcoming	N/A	N/A
Weight loss	Adults with obesity with or without type 2	Phase II Upcoming	N/A	N/A
Weight loss	Weight loss study for overweight adults	Phase III Upcoming	N/A	N/A
Weight loss	Weight loss study for overweight adults	Phase III Upcoming	N/A	N/A
Weight loss w/ type 2 diabetes	Adults with obesity and T2DM	Phase III Upcoming	N/A	N/A

Recruitment Reach and Pipeline Capacity

Capability / Metric	Result	Sponsor / CRO Benefit
COPC patient access	535,000+ across 80+ Central Ohio locations	A vast, community-based population to draw from
Prescreened volunteer database	22,000+	An established, research-engaged populace ready for rapid outreach
Dedicated obesity-interest pipeline	Thousands prescreened	Kept engaged and segmented by protocol fit, ready for current and future studies
Disease state segmentation	Obesity, overweight, T2D, hypertension, and CV disease	Reduces direct competition across concurrent studies
Additional-study capacity	Scalable through EMR, COPC, and community outreach	Room to take on new awards without straining current pipeline

Specialized Site Capabilities

- **Facility and laboratory infrastructure:** A 7,500 sq. ft. site with eight treatment rooms, five overnight rooms, four monitor rooms, controlled IP storage, continuous temperature monitoring, and -80°C freezer capacity.
- **Rapid feasibility and start-up:** Feasibility turnaround targeted within 24–48 hours. Budget/CTA turnaround targeted at about one week. Start-up targeted within 2–4 weeks.
- **Clinical expertise:** Internal medicine, GI/obesity, and cardiopulmonary specialists on staff.
- **Recruitment operations:** Extensive site database, access to a primary care network and private practice EMRs, provider and community outreach, tailored advertising, established SOPs, and responsive sponsor/CRO support.

Remington-Davis has a consistent record of meeting or exceeding enrollment targets, experienced PI leadership, dietitian-supported retention, and scalable patient access. Backed by a thousands-strong pre-screened obesity pipeline, the site gives sponsors and CRO teams confidence in current delivery and room to take on more.

[Learn more about RDI.](#)